Skip to main content
Top
Published in: Infection 3/2015

01-06-2015 | Original Paper

Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in kidney transplant recipients

Authors: Maristela P. Freire, Edson Abdala, Maria L. Moura, Flávio Jota de Paula, Fernanda Spadão, Hélio H. Caiaffa-Filho, Elias David-Neto, William C. Nahas, Ligia C. Pierrotti

Published in: Infection | Issue 3/2015

Login to get access

Abstract

Introduction

Solid organ transplant recipients are especially susceptible to healthcare-associated infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp-HAIs). The aim of the study was to evaluate risk factors and outcome of these infections in kidney transplant recipients.

Methods

This was a retrospective cohort of kidney transplant (KTx) recipients between January 2009 and December 2013. Cases were defined as patients who developed KPC-Kp-HAI, confirmed by PCR for bla KPC gene after KTx during the study period. We analysed variables related to recipient; induction immunosuppressant therapy; delayed graft function; use of invasive devices; SOFA score on the first day of infection; type of therapy; time from positive culture to appropriate antimicrobial therapy; bacteraemia; and concomitant infection. Outcome measures were the occurrence of KPC-Kp-HAI and 30-day mortality after KPC-Kp-HAI.

Results

A total of 1,101 were submitted to KTx in the period, 21 patients were classified as infected with KPC-Kp. Another ten patients had KPC-Kp-HAI in the period and were transplanted before 2009. Of those 31 patients, 48.4 % showed evidence of prior colonization and 38.7 % had bacteraemia. The most common site of infection was the surgical wound. Risk factors for KPC-Kp-HAI were multi-organ transplantation and the use of a ureteral stent. Eight of the infected patients experienced recurrence of the infection. The 30-day mortality rate was 41.9 %. Survival was significantly lower among the patients with KPC-Kp-HAI (72 vs. 89.1 %; P = 0.002). The only risk factor independently associated with 30-day mortality was an elevated SOFA score on the first day of infection.

Conclusions

In KTx recipients, the occurrence of KPC-Kp-HAI was related to invasive devices and type of transplant; these infections had a high rate of recurrence and reduced survival after KTx.
Literature
2.
go back to reference Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56:128–32.CrossRefPubMed Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56:128–32.CrossRefPubMed
3.
go back to reference Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96.CrossRefPubMed Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96.CrossRefPubMed
4.
go back to reference Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36.CrossRefPubMed Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36.CrossRefPubMed
5.
go back to reference Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–5.CrossRefPubMedCentralPubMed Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–5.CrossRefPubMedCentralPubMed
6.
go back to reference Gyung Y, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist. 2005;11:165–8.CrossRef Gyung Y, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist. 2005;11:165–8.CrossRef
7.
go back to reference Orsi GB, Bencardino A, Vena A, et al. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study. Infection. 2013;41:61–7.CrossRefPubMed Orsi GB, Bencardino A, Vena A, et al. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study. Infection. 2013;41:61–7.CrossRefPubMed
8.
go back to reference Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–106.CrossRefPubMed Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–106.CrossRefPubMed
9.
go back to reference Schwaber MJ, Klarfeld-Lidji S. Navon-Venezia, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028–33.CrossRefPubMedCentralPubMed Schwaber MJ, Klarfeld-Lidji S. Navon-Venezia, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028–33.CrossRefPubMedCentralPubMed
10.
go back to reference Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology and outcome. Antimicrob Agents Chemother. 2008;52:1413–8.CrossRefPubMedCentralPubMed Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology and outcome. Antimicrob Agents Chemother. 2008;52:1413–8.CrossRefPubMedCentralPubMed
11.
go back to reference Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of Combination Therapy. Clin Infect Dis. 2012;55:943–50.CrossRefPubMed Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of Combination Therapy. Clin Infect Dis. 2012;55:943–50.CrossRefPubMed
12.
go back to reference Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14:198–205.CrossRefPubMed Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14:198–205.CrossRefPubMed
13.
go back to reference Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 2013;13:2619–33.CrossRefPubMedCentralPubMed Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 2013;13:2619–33.CrossRefPubMedCentralPubMed
14.
go back to reference Lübbert C, Becker-Rux D, Rodloff AC, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case—control analysis. Infection. 2014;42:309–16.CrossRefPubMed Lübbert C, Becker-Rux D, Rodloff AC, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case—control analysis. Infection. 2014;42:309–16.CrossRefPubMed
15.
go back to reference Taglietti F, Di Bella S, Galati V, Topino S, Iappelli M, Petrosillo N. Carbapenemase-producing Klebsiella pneumoniae-related mortality among solid organ-transplanted patients: do we know enough? Transpl Infect Dis. 2013;15:E164–5.CrossRefPubMed Taglietti F, Di Bella S, Galati V, Topino S, Iappelli M, Petrosillo N. Carbapenemase-producing Klebsiella pneumoniae-related mortality among solid organ-transplanted patients: do we know enough? Transpl Infect Dis. 2013;15:E164–5.CrossRefPubMed
16.
go back to reference Kalpoe JS, Sonnenberg E, Factor SH, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012;18:468–74.CrossRefPubMed Kalpoe JS, Sonnenberg E, Factor SH, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012;18:468–74.CrossRefPubMed
17.
go back to reference Cicora F, Mos F, Paz M, Allende NG, Roberti J. Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients: a retrospective study. Transpl Proc. 2013;45:3389–93.CrossRef Cicora F, Mos F, Paz M, Allende NG, Roberti J. Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients: a retrospective study. Transpl Proc. 2013;45:3389–93.CrossRef
18.
go back to reference Simkins J, Muggia V, Cohen HW, Minamoto GY. Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: a case-control study. Traspl Infect Dis. 2014;16:775–82.CrossRef Simkins J, Muggia V, Cohen HW, Minamoto GY. Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: a case-control study. Traspl Infect Dis. 2014;16:775–82.CrossRef
19.
go back to reference Horan CT, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infec Control. 2008;36:309–32.CrossRef Horan CT, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infec Control. 2008;36:309–32.CrossRef
20.
go back to reference Ljungman P, Griffiths P, Paya C. Definitions of Cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.CrossRefPubMed Ljungman P, Griffiths P, Paya C. Definitions of Cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.CrossRefPubMed
21.
go back to reference Freire MP, Antonopoulos IM, Piovesan AC et al. Amikacin prophylaxis and risk factors for surgical site infection after kidney transplantation. Transplantation. 2014; (Epub ahead of print). Freire MP, Antonopoulos IM, Piovesan AC et al. Amikacin prophylaxis and risk factors for surgical site infection after kidney transplantation. Transplantation. 2014; (Epub ahead of print).
22.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement; M100-S22. Wayne: CLSI; 2012. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement; M100-S22. Wayne: CLSI; 2012.
25.
go back to reference Satlin MJ, Jenkins SG, Walsh TJ. The Global challenge of Carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58:1274–83.CrossRefPubMedCentralPubMed Satlin MJ, Jenkins SG, Walsh TJ. The Global challenge of Carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58:1274–83.CrossRefPubMedCentralPubMed
26.
go back to reference Wilson CH, Rix DA, Manas DM. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev. 2013, 6:CD004925. Wilson CH, Rix DA, Manas DM. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev. 2013, 6:CD004925.
27.
go back to reference Lee JR, Bang H, Dadhania D, et al. Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients. Transplantation. 2013;96:732–8.CrossRefPubMed Lee JR, Bang H, Dadhania D, et al. Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients. Transplantation. 2013;96:732–8.CrossRefPubMed
28.
go back to reference Hyle EP, Ferraro MJ, Silver M, Lee H, Hoope DC. Ertapenem-resistant Enterobacteriaceae: risk Factors for acquisition and outcomes. Infect Control Hosp Epidemiol. 2010;31:1242–9.CrossRefPubMed Hyle EP, Ferraro MJ, Silver M, Lee H, Hoope DC. Ertapenem-resistant Enterobacteriaceae: risk Factors for acquisition and outcomes. Infect Control Hosp Epidemiol. 2010;31:1242–9.CrossRefPubMed
29.
go back to reference Vidal E, Torre-Cisneros J, Blanes M, et al. Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort. Transpl Infect Dis. 2012;14:595–603.CrossRefPubMed Vidal E, Torre-Cisneros J, Blanes M, et al. Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort. Transpl Infect Dis. 2012;14:595–603.CrossRefPubMed
30.
go back to reference Sorto R, Irizar SS, Delgadillo G, Alberú J, Correa-Rotter R, Morales-Buenrostro LE. Risk factors for urinary tract infections during the first year after kidney transplantation. Transplant Proc. 2010;42:280–1.CrossRefPubMed Sorto R, Irizar SS, Delgadillo G, Alberú J, Correa-Rotter R, Morales-Buenrostro LE. Risk factors for urinary tract infections during the first year after kidney transplantation. Transplant Proc. 2010;42:280–1.CrossRefPubMed
31.
go back to reference Bodro M, Sabe N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96:843–9.CrossRefPubMed Bodro M, Sabe N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96:843–9.CrossRefPubMed
32.
go back to reference Linares L, Cervera C, Hoyo I, et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc. 2010;42:2941–3.CrossRefPubMed Linares L, Cervera C, Hoyo I, et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc. 2010;42:2941–3.CrossRefPubMed
33.
go back to reference Winters HA, Parbhoo RK, Schafer JJ, Goff DA. Extended-spectrum beta-lactamase-producing bacterial infections in adult solid organ transplant recipients. Ann Pharmacother. 2011;45:309–16.CrossRefPubMed Winters HA, Parbhoo RK, Schafer JJ, Goff DA. Extended-spectrum beta-lactamase-producing bacterial infections in adult solid organ transplant recipients. Ann Pharmacother. 2011;45:309–16.CrossRefPubMed
34.
go back to reference Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–13.CrossRefPubMedCentralPubMed Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–13.CrossRefPubMedCentralPubMed
35.
go back to reference Zavascki AP, Bulitta JB, Landersdorfe CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther. 2013;11:1333–53.CrossRefPubMed Zavascki AP, Bulitta JB, Landersdorfe CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther. 2013;11:1333–53.CrossRefPubMed
36.
go back to reference Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-Negative bacteria. Clin Microbiol Rev. 2012;25:450–70.CrossRefPubMedCentralPubMed Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-Negative bacteria. Clin Microbiol Rev. 2012;25:450–70.CrossRefPubMedCentralPubMed
37.
go back to reference Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin b in critically ill patients. Clin Infect Dis. 2008;47:1298–304.CrossRefPubMed Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin b in critically ill patients. Clin Infect Dis. 2008;47:1298–304.CrossRefPubMed
38.
go back to reference Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–94.CrossRefPubMedCentralPubMed Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–94.CrossRefPubMedCentralPubMed
39.
go back to reference Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012;7:e52349.CrossRefPubMedCentralPubMed Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012;7:e52349.CrossRefPubMedCentralPubMed
40.
go back to reference Freire MP, Van Der Heijden IM, Prado GV, et al. Polymyxin use as risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation. Transpl Infect Dis. 2014;16:369–78.CrossRefPubMed Freire MP, Van Der Heijden IM, Prado GV, et al. Polymyxin use as risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation. Transpl Infect Dis. 2014;16:369–78.CrossRefPubMed
41.
go back to reference Freire MP, Pierrotti LC, Filho HH et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur J Clin Microbiol Infect Dis. 2015;34:277–86.CrossRefPubMed Freire MP, Pierrotti LC, Filho HH et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur J Clin Microbiol Infect Dis. 2015;34:277–86.CrossRefPubMed
Metadata
Title
Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in kidney transplant recipients
Authors
Maristela P. Freire
Edson Abdala
Maria L. Moura
Flávio Jota de Paula
Fernanda Spadão
Hélio H. Caiaffa-Filho
Elias David-Neto
William C. Nahas
Ligia C. Pierrotti
Publication date
01-06-2015
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 3/2015
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0743-4

Other articles of this Issue 3/2015

Infection 3/2015 Go to the issue